Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 11/2023

08.11.2023 | Heart Failure (HJ Eisen, Section Editor)

Genetic Engineering of Donor Pig for the First Human Cardiac Xenotransplantation: Combatting Rejection, Coagulopathy, Inflammation, and Excessive Growth

verfasst von: Shreya Singireddy, Andy Tully, Javier Galindo, David Ayares, Avneesh K. Singh, Muhammad M. Mohiuddin

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The first successful pig to human cardiac xenotransplantation in January 2022 represented a major step forward in the fields of heart failure, immunology, and applied genetic engineering, using a 10-gene edited (GE) pig. This review summarizes the evolution of preclinical modelling data which informed the use of each of the 10 genes modified in the 10-GE pig: GGTA1, Β4GalNT2, CMAH, CD46, CD55, TBM, EPCR, CD47, HO-1, and growth hormone receptor.

Recent Findings

The translation of the 10-GE pig from preclinical modelling to clinical compassionate xenotransplant use was the culmination of decades of research combating rejection, coagulopathy, inflammation, and excessive xenograft growth.

Summary

Understanding these 10 genes with a view to their combinatorial effects will be useful in anticipated xenotransplant clinical trials.
Literatur
1.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.CrossRefPubMed
2.
Kilic A, Mathier MA, Hickey GW, Sultan I, Morell VO, Mulukutla SR, et al. Evolving trends in adult heart transplant with the 2018 heart allocation policy change. JAMA Cardiol. 2021;6(2):159–167.
3.
Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau CL, Shah A, et al. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med. 2022;387(1):35–44.CrossRefPubMedPubMedCentral
4.
•• Mohiuddin MM, Singh AK, Scobie L, Goerlich CE, Grazioli A, Saharia K, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. 2023. This is the definitive postmortem analysis from the first successful pig to human solid organ xenotransplant, reviewing both the evidence for success as well as areas for further investigation.
5.
Cooper DKC, Hara H, Iwase H, Yamamoto T, Li Q, Ezzelarab M, et al. Justification of specific genetic modifications in pigs for clinical organ xenotransplantation. Xenotransplantation. 2019;26(4):e12516.CrossRefPubMedPubMedCentral
6.
• Singh AK, Goerlich CE, Shah AM, Zhang T, Tatarov I, Ayares D, et al. Cardiac xenotransplantation: progress in preclinical models and prospects for clinical translation. Transpl Int. 2022;35:10171. This paper reviews the crucial breakthroughs that have sprung from pre-clinical modelling and previews future directions of xenotransplantation study.
7.
Niu D, Wei HJ, Lin L, George H, Wang T, Lee IH, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science. 2017;357(6357):1303–7.CrossRefPubMedPubMedCentral
8.
Ladowski JM, Martens GR, Reyes LM, Hauptfeld-Dolejsek V, Tector M, Tector J. Examining epitope mutagenesis as a strategy to reduce and eliminate human antibody binding to class II swine leukocyte antigens. Immunogenetics. 2019;71(7):479–487.
9.
Schuurman H, Cheng J, Lam T. Pathology of xenograft rejection: a commentary. Xenotransplantation (Københaven). 2003;10(4):293–9.CrossRef
10.
11.
Singh AK, Chan JL, DiChiacchio L, Hardy NL, Corcoran PC, Lewis BGT, et al. Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs. Xenotransplantation. 2019;26(2):e12465.CrossRefPubMed
12.
Simon PM, Neethling FA, Taniguchi S, Goode PL, Zopf D, Hancock WW, et al. Intravenous infusion of Galα1–3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation. 1998;65(3):346–353.
13.
Azimzadeh A, Meyer C, Watier H, Beller J, Chenard-Neu M, Kieny R, et al. Removal of primate xenoreactive natural antibodies by extracorporeal perfusion of pig kidneys and livers. Transpl Immunol. 1998;6(1):13–22.
14.
Cooper DKC, Kuwaki K, Tseng Y, Dor, Frank J M F, Shimizu A, Houser SL, et al. Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med. 2005;11(1):29–31.
15.
Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen S, et al. Production of α1,3-galactosyltransferase: deficient pigs. Science (American Association for the Advancement of Science). 2003;299(5605):411–414.
16.
Galili U. Induced anti-non gal antibodies in human xenograft recipients. Transplantation. 2012;93(1):11–16.
17.
McGregor CG, Ricci D, Miyagi N, Stalboerger PG, Du Z, Oehler EA, et al. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts. Transplantation. 2012;93(7):686–92.CrossRefPubMedPubMedCentral
18.
Zhao C, Cooper DKC, Dai Y, Hara H, Cai Z, Mou L. The Sda and Cad glycan antigens and their glycosyltransferase, β1,4GalNAcT‐II, in xenotransplantation. Xenotransplantation (Københaven). 2018;25(2):e12386-n/a.
19.
Byrne GW, Stalboerger PG, Du Z, Davis TR, McGregor CG. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation. 2011;91(3):287–92.CrossRefPubMedPubMedCentral
20.
Estrada JL, Martens G, Li P, Adams A, Newell KA, Ford ML, et al. Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA 1/ CMAH /β4Gal NT 2 genes. Xenotransplantation (Københaven). 2015;22(3):194–202.CrossRef
21.
Altman MO, Gagneux P. Absence of Neu5Gc and presence of anti-Neu5Gc antibodies in humans—an evolutionary perspective. Front Immunol. 2019;10:789.
22.
Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation (Københaven). 2002;9(6):376–81.CrossRef
23.
Burlak C, Paris LL, Lutz AJ, Sidner RA, Estrada J, Li P, et al. Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs. Am J Transplant. 2014;14(8):1895–900.CrossRefPubMedPubMedCentral
24.
Wang Z, Li P, Butler JR, Blankenship RL, Downey SM, Montgomery JB, et al. Immunogenicity of renal microvascular endothelial cells from genetically modified pigs. Transplantation. 2016;100(3):533–537.
25.
Yamamoto T, Iwase H, Patel D, Jagdale A, Ayares D, Anderson D, et al. Old World Monkeys are less than ideal transplantation models for testing pig organs lacking three carbohydrate antigens (Triple-Knockout). Sci Rep. 2020;10(1):9771.CrossRefPubMedPubMedCentral
26.
Diamond LE, Quinn CM, Martin MJ, Lawson J, Platt JL, Logan JS. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation. 2001;71(1):132–42.CrossRefPubMed
27.
28.
Shimizu I, Smith NR, Guiling Z, Medof E, Sykes M. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-αGal natural antibodies. Transplantation. 2006;81(1):95–100.
29.
Schuurman H, Pino-Chavez G, Phillips MJ, Thomas L, White DJG, Cozzi E. Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation. 2002;73(7):1146–1151.
30.
Waterworth PD, Cozzi E, Tolan MJ, Langford G, Braidley P, Chavez G, et al. Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy. Transplant Proc. 1997;29(1):899–900.
31.
Azimzadeh AM, Kelishadi SS, Ezzelarab MB, Singh AK, Stoddard T, Iwase H, et al. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway-regulatory protein. Xenotransplantation (Københaven). 2015;22(4):310–6.CrossRef
32.
Miyagawa S, Shirakura R, Iwata K, Nakata S, Matsumiya G, Izutani H, et al. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis. Transplantation. 1994;58(7):834–40.CrossRefPubMed
33.
Fischer K, Kraner-Scheiber S, Petersen B, Rieblinger B, Buermann A, Flisikowska T, et al. Efficient production of multi-modified pigs for xenotransplantation by ‘combineering’, gene stacking and gene editing. Sci Rep. 2016;6(1):29081.
34.
Byrne GW, Mccurry KR, Martin MJ, Mcclellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation. 1997;63(1):149–155.
35.
Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D. Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59. Cell Rep. 2013;3(5):1369–77.CrossRefPubMedPubMedCentral
36.
Aigner B, Klymiuk N, Wolf E. Transgenic pigs for xenotransplantation: selection of promoter sequences for reliable transgene expression. Curr Opin Organ Transplant. 2010;15(2):201–6.CrossRefPubMed
37.
38.
Salvaris EJ, Moran CJ, Roussel JC, Fisicaro N, Robson SC, Cowan PJ. Pig endothelial protein C receptor is functionally compatible with the human protein C pathway. Xenotransplantation. 2020;27(2):e12557.CrossRefPubMed
39.
Crikis S, Zhang XM, Dezfouli S, Dwyer KM, Murray-Segal LM, Salvaris E, et al. Antiinflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice. Am J Transplant. 2010;10(2):242–50.CrossRefPubMedPubMedCentral
40.
Mohiuddin MM, Singh AK, Corcoran PC, Thomas Iii ML, Clark T, Lewis BG, et al. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. Nat Commun. 2016;7:11138.
41.
Iwase H, Hara H, Ezzelarab M, Li T, Zhang Z, Gao B, et al. Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts. Xenotransplantation. 2017;24(2).
42.
Ide K, Wang H, Tahara H, Liu J, Wang X, Asahara T, et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A. 2007;104(12):5062–6.CrossRefPubMedPubMedCentral
43.
Yan JJ, Koo TY, Lee HS, Lee WB, Kang B, Lee JG, et al. Role of human CD200 overexpression in pig-to-human xenogeneic immune response compared with human CD47 overexpression. Transplantation. 2018;102(3):406–16.CrossRefPubMed
44.
Tena A, Sachs DH, Mallard C, Yang Y, Tasaki M, Farkash E, et al. Prolonged survival of pig skin on baboons following administration of pig cells expressing human CD47. Transplantation. 2017;101(2):316–321.
45.
Takeuchi K, Ariyoshi Y, Shimizu A, Okumura Y, Cara-Fuentes G, Garcia GE, et al. Expression of human CD47 in pig glomeruli prevents proteinuria and prolongs graft survival following pig-to-baboon xenotransplantation. Xenotransplantation. 2021;28(6):e12708.CrossRefPubMedPubMedCentral
46.
Camara NO, Soares MP. Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med. 2005;38(4):426–35.CrossRefPubMed
47.
Petersen B, Ramackers W, Lucas-Hahn A, Lemme E, Hassel P, Queißer A, et al. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation (Københaven). 2011;18(6):355–68.CrossRef
48.
Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med. 1998;4(9):1073–7.CrossRefPubMed
49.
Goerlich CE, Griffith B, Hanna P, Hong SN, Ayares D, Singh AK, et al. The growth of xenotransplanted hearts can be reduced with growth hormone receptor knockout pig donors. J Thorac Cardiovasc Surg. 2023;165(2):e69–81.CrossRefPubMed
50.
Hinrichs A, Riedel EO, Klymiuk N, Blutke A, Kemter E, Längin M, et al. Growth hormone receptor knockout to reduce the size of donor pigs for preclinical xenotransplantation studies. Xenotransplantation. 2021;28(2):e12664.CrossRefPubMed
51.
Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab. 2014;25(3):128–137.
52.
Mohiuddin MM, Singh AK, Scobie L, Goerlich CE, Grazioli A, Saharia K, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. 2023;402(10399):397–410.CrossRefPubMed
53.
Montgomery RA, Stern JM, Lonze BE, Tatapudi VS, Mangiola M, Wu M, et al. Results of two cases of pig-to-human kidney xenotransplantation. N Engl J Med. 2022;386(20):1889–98.CrossRefPubMed
54.
Porrett PM, Orandi BJ, Kumar V, Houp J, Anderson D, Cozette Killian A, et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant. 2022;22(4):1037–53.CrossRefPubMed
Metadaten
Titel
Genetic Engineering of Donor Pig for the First Human Cardiac Xenotransplantation: Combatting Rejection, Coagulopathy, Inflammation, and Excessive Growth
verfasst von
Shreya Singireddy
Andy Tully
Javier Galindo
David Ayares
Avneesh K. Singh
Muhammad M. Mohiuddin
Publikationsdatum
08.11.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01978-4

Weitere Artikel der Ausgabe 11/2023

Current Cardiology Reports 11/2023 Zur Ausgabe

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Long-Term Remote vs. Conventional Monitoring of Pacemakers: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Diversity and Health Equity in Cardiology (AE Johnson, Section Editor)

Preventing Heart Failure Readmission in Patients with Low Socioeconomic Position

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease

Interventional Cardiology (SR Bailey and T Helmy, Section Editors)

The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen